Shockwave Medical Intrinsic Value – SHOCKWAVE MEDICAL Reports 41.6% Increase in Revenue for Third Quarter of FY2023
November 27, 2023
☀️Earnings Overview
For the third quarter of FY2023, SHOCKWAVE MEDICAL ($NASDAQ:SWAV) reported total revenue of USD 186.0 million, a 41.6% increase from the same period in the previous year. Net income for the quarter remained at USD 35.0 million, compared to the same quarter in 2023.
Analysis – Shockwave Medical Intrinsic Value
GoodWhale has conducted an in-depth analysis of SHOCKWAVE MEDICAL’s financials and concluded that its fair value is around $460.7, as calculated by our proprietary Valuation Line. This could represent a great opportunity for investors to acquire SHOCKWAVE MEDICAL stock at a discount. At GoodWhale, we believe that conducting thorough research and analysis of the financials of a company, such as SHOCKWAVE MEDICAL, can help investors make informed decisions. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Shockwave Medical. More…
| Total Revenues | Net Income | Net Margin |
| 671.28 | 243.88 | 36.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Shockwave Medical. More…
| Operations | Investing | Financing |
| 176.79 | -418.74 | 610.16 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Shockwave Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.47k | 872.71 | 16.3 |
Key Ratios Snapshot
Some of the financial key ratios for Shockwave Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 124.4% | – | 25.1% |
| FCF Margin | ROE | ROA |
| 21.3% | 17.3% | 7.1% |
Peers
The medical device industry is an ever-evolving landscape, with many companies competing to develop the most impactful and innovative solutions. One of the major players in this field is ShockWave Medical Inc, which has recently been engaged in a fierce competition with other notable players such as Inspire Medical Systems Inc, Inari Medical Inc, and INVO Bioscience Inc. Each of these companies has their own unique approach to developing cutting-edge medical technology, and their competition is driving innovation and progress in the industry.
– Inspire Medical Systems Inc ($NYSE:INSP)
Inspire Medical Systems Inc is a medical device company that specializes in the development of minimally invasive solutions for treating obstructive sleep apnea (OSA). The company has a market capitalization of 6.71 billion US dollars as of 2022, making it one of the larger companies in its sector. The company’s Return on Equity (ROE) is -8.55%, which suggests that the company is not generating a positive return on its shareholders’ investments. This is likely due to the high costs associated with R&D and clinical trials associated with developing new products and treatments. Despite this, Inspire Medical Systems Inc remains a leader in its sector, having developed innovative solutions that are helping to improve the lives of patients around the world.
– Inari Medical Inc ($NASDAQ:NARI)
Inari Medical Inc is a medical technology company that develops innovative medical devices for treating vascular diseases. The company has a market cap of 3.67 billion USD as of 2022, indicating a strong market presence and demonstrating that investors are confident in the company’s long-term prospects. Additionally, Inari Medical Inc has a return on equity of -2.93%, which suggests that the company has not been able to generate profits from its investments. This could be due to the company’s investments into research and development, as well as its expensive start-up costs.
– INVO Bioscience Inc ($NASDAQ:INVO)
INVO Bioscience Inc is a medical device company that focuses on developing and commercializing innovative products for the treatment of infertility. The company has a market cap of 7.3M as of 2022, indicating that its current market value is relatively small compared to its competitors. Its Return on Equity of -210.86% shows that the company is not performing well, as it has been burning through cash and not generating sufficient returns on its investments.
Summary
Investors may be encouraged by SHOCKWAVE MEDICAL‘s reported 3rd quarter results, with total revenue of USD 186 million, representing a 41.6% year-on-year increase. Net income remained unchanged from the same quarter in 2023 at USD 35 million, and the company’s robust growth demonstrates strong performance and potential. With the stock experiencing strong growth over the past year, investors will keenly watch the company’s development in the coming quarters to assess its long-term prospects.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
